Premise: Leaf mass per area (LMA) is a widely used functional trait in both neobotanical and paleobotanical research that provides a window into how plants interact with their environment. Paleobotanists have used site-level measures of LMA as a proxy for climate, biome, deciduousness, and community-scale plant strategy, yet many of these relationships have not been grounded in modern data. In this study, we evaluated LMA from the paleobotanical perspective, seeking to add modern context to paleobotanical interpretations and discover what a combined modern and fossil data set can tell us about how LMA can be best applied toward interpreting plant communities.
Methods: We built a modern data set by pulling plant trait data from the TRY database, and a fossil data set by compiling data from studies that have used the petiole-width proxy for LMA. We then investigated the relationships of species-mean, site-mean, and site-distribution LMA with different climatic, phylogenetic, and physiognomic variables.
Results: We found that LMA distributions are correlated with climate, site taxonomic composition, and deciduousness. However, the relative contributions of these factors are not distinctive, and ultimately, LMA distributions cannot accurately reconstruct the biome or climate of an individual site.
Conclusions: The correlations that make up the leaf economics spectrum are stronger than the correlations between LMA and climate, phylogeny, morphospace, or depositional environment. Fossil LMA should be understood as the culmination of the influences of these variables rather than as a predictor.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/ajb2.16419 | DOI Listing |
JCO Clin Cancer Inform
January 2025
Machine Learning Department, H. Lee Moffit Cancer Center and Research Institute, Tampa, FL.
Purpose: Adaptive radiotherapy accounts for interfractional anatomic changes. We hypothesize that changes in the gross tumor volumes identified during daily scans could be analyzed using delta-radiomics to predict disease progression events. We evaluated whether an auxiliary data set could improve prediction performance.
View Article and Find Full Text PDFPLoS One
January 2025
Social & Scientific Systems, Inc., a DLH Holdings Company / United States Agency for International Development Strategic Information Technical Support Activity, Kampala, Uganda.
Tuberculosis (TB) stigma remains a significant barrier to TB control efforts globally, especially in countries with a high TB burden. Studies about TB stigma done in Uganda so far have been limited in scope and focused on data collected health facilities. In this study we report TB related stigma at community level for the period 2021/2022.
View Article and Find Full Text PDFStat Med
February 2025
Department of Statistics and Data Science, National University of Singapore, Singapore, Singapore.
The additive hazard model, which focuses on risk differences rather than risk ratios, has been widely applied in practice. In this paper, we consider an additive hazard model with varying coefficients to analyze recurrent events data. The model allows for both varying and constant coefficients.
View Article and Find Full Text PDFJAMA Netw Open
January 2025
RAND Health, RAND, Boston, Massachusetts.
Importance: Long-term nursing home stay or death (long-term NH stay or death), defined as new long-term residence in a nursing home or death following hospital discharge, is an important patient-centered outcome.
Objective: To examine whether the COVID-19 pandemic was associated with changes in long-term NH stay or death among older adults with sepsis, and whether these changes were greater in individuals from racial and ethnic minoritized groups.
Design, Setting, And Participants: This cross-sectional study used patient-level data from the Medicare Provider Analysis and Review File, the Master Beneficiary Summary File, and the Minimum Data Set.
Blood Adv
January 2025
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States.
Some CLL patients who develop progressive disease (PD) during treatment with covalent Bruton tyrosine kinase inhibitors (cBTKi) acquire pathway resistance mutations in BTK or PLCG2. Here, we report gene mutation data from paired baseline and PD peripheral blood samples from 52 patients (zanubrutinib, n=24; ibrutinib, n=28) who, at an early median follow-up time of 25.7 months, progressed on zanubrutinib or ibrutinib treatment in the ALPINE trial (NCT03734016).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!